Summit Clinical Research, LLC (“Summit”) is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. He will be remembered as a visionary leader, renowned researcher, trusted collaborator, patient advocate, patriot, and physician as well as a dedicated husband, father, and friend.
During an illustrious 30-year career, Dr. Harrison pioneered the field of liver research and worked tirelessly in the pursuit of finding new treatment options and cures for Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). He revolutionized Hepatology and the greater research community. Dr. Harrison was instrumental in the achievement of the first FDA-approved drug to treat patients with MASH / MASLD.
Summit remains firmly committed to Dr. Harrison’s legacy and to achieving his vision of revolutionizing the way clinical trials are executed for the future of our industry. Together we created a strong foundation at Summit through a deep and clinically driven team leveraging the scientific collaboration of world-renowned academic experts. This team remains in place today and, with the stalwart support from the luminaries of the field, will continue to further accelerate the progress of clinical research.
Read the press release
